When Does a Medical Device No Longer Need a 510(k)?

On October 6, 2026, the U.S. Food and Drug Administration expanded existing 510(k) exemptions covering 14 categories of Class II clinical toxicology devices.

Just 19 days earlier, FDA published a final order denying a proposed partial exemption for certain radiology computer-aided detection, diagnosis, and triage devices.

Two decisions. Two different outcomes.

What makes this particularly interesting is that both decisions arose under the same statutory framework for determining when premarket notification is necessary to assure device safety and effectiveness.

The distinction deserves attention from medical device manufacturers, particularly those developing diagnostic technologies, software-based medical devices, and AI-enabled products.

1. FDA expands 510(k) exemptions for clinical toxicology devices

On October 6, FDA issued a final order expanding existing premarket notification exemptions for 14 Class II clinical toxicology device types.

These include certain test systems for amphetamines, cannabinoids, cocaine, methamphetamine, opiates, and other substances.

The affected device types already benefited from limited exemptions for employment and insurance testing. The October decision removes the previous exclusion for qualifying devices intended for federal drug-testing programs.

The important qualification is that these exemptions are not unrestricted.

Manufacturers must still comply with the applicable limitations under 21 CFR 862.9 and the specific classification regulations. Eligible devices must be intended for employment and insurance testing and carry the required intended-use labeling.

A clinical diagnostic application does not automatically qualify simply because the device measures the same substance.

The distinction can materially affect a manufacturer's submission strategy, development budget, and market-entry timeline.

A particularly noteworthy example: fentanyl testing

In its final order, FDA explicitly addressed whether certain fentanyl test systems could qualify for the expanded exemption.

FDA explained that these products generally fall within the opiate test system classification under 21 CFR 862.3650. Qualifying products previously associated with product code DJG may fall under exempt product code PVH, provided the applicable exemption limitations are satisfied.

This is a meaningful detail for manufacturers developing workplace drug-testing technology.

However, exemption from 510(k) notification does not eliminate applicable requirements relating to quality management systems, establishment registration, device listing, labeling, or medical device reporting.

2. FDA denies an exemption petition for radiology software

The second decision presents a contrasting regulatory outcome.

On September 17, 2026, FDA published its final order concerning a petition submitted on behalf of Harrison.ai seeking conditional exemptions for several categories of radiology computer-aided detection and diagnosis software.

The petition addressed six product codes:

The petition proposed conditions involving manufacturers with previous FDA clearances, continued compliance with regulatory controls, and additional postmarket measures.

FDA denied the petition on April 1, 2026, with the final order published September 17.

The Agency determined that the information presented did not establish that premarket notification was unnecessary to assure safety and effectiveness for the devices covered by the proposed exemption.

Consequently, applicable 510(k) clearance requirements remain in place.

Importantly, this decision should not be interpreted as a rejection of medical AI or as a determination that AI devices can never qualify for exemptions.

The decision concerns the particular device types and exemption conditions proposed in the petition.

3. What explains the different outcomes?

Under section 510(m) of the Federal Food, Drug, and Cosmetic Act, FDA may exempt qualifying Class II device types from premarket notification requirements when the Agency determines that a 510(k) is not necessary to assure safety and effectiveness.

FDA generally considers several factors:

• Whether the device has a significant history of safety risks or misleading claims.
• Whether the characteristics necessary for safe and effective performance are well established.
• Whether changes affecting safety or effectiveness can be detected before harm occurs, or would not materially increase risk.
• Whether modifications are likely to change the device's classification.

The Agency also considers the available device experience, relevant controls, and limitations that can appropriately restrict an exemption.

These factors provide a useful framework for understanding both recent orders.

However, the two outcomes should not be reduced to a simple conclusion that traditional diagnostic technologies are becoming exempt while AI technologies face additional restrictions.

The petitions, product categories, intended uses, and supporting regulatory records were different.

The more defensible conclusion is that FDA continues to evaluate whether premarket review is necessary for specific device types under defined conditions.

4. What manufacturers should do now

These decisions reinforce the importance of establishing the appropriate regulatory pathway before committing resources to a premarket submission.

Manufacturers should examine five questions.

First, is the device correctly classified?

Verify the applicable regulation number, product code, device classification, and current exemption status. A product code is an important starting point, but it does not independently establish that a particular product is exempt.

Second, does the intended use fall within the exemption?

A device may be exempt for one intended use while requiring premarket notification for another. Claims and labeling can materially affect the regulatory determination.

Third, does the technology remain within the exemption limitations?

Differences in fundamental scientific technology, device characteristics, or the consequences of an incorrect result can change the applicable requirements.

Fourth, which obligations continue to apply?

510(k) exemption is not an exemption from FDA regulation. Applicable general controls, special controls, quality system requirements, labeling obligations, and postmarket responsibilities must still be assessed.

Fifth, is the regulatory justification documented?

Manufacturers should maintain a defensible record explaining their classification, intended-use interpretation, exemption assessment, and remaining compliance obligations.

Where classification or exemption applicability remains uncertain, FDA's Section 513(g) process may provide a mechanism to request information from the Agency.

5. The broader implication for regulatory strategy

These two decisions illustrate why a medical device regulatory strategy should not begin with the assumption that a particular submission is required.

It should begin with a disciplined assessment of the device itself, its intended use, its technological characteristics, and the regulatory framework applicable to that specific product.

For qualifying manufacturers, correctly identifying an exemption can prevent unnecessary submission work.

For manufacturers whose products remain subject to 510(k), understanding the applicable requirements early can improve evidence planning, submission preparation, and resource allocation.

The consequences of getting that determination wrong can be substantial.

The Panabistics perspective

At Panabistics, we believe effective regulatory planning begins before submission preparation.

Our Regulatory Intelligence platform supports structured U.S. Regulatory Strategy Development, including assessment of device characteristics, regulatory pathways, and anticipated evidence requirements.

For products pursuing the 510(k) pathway, our FDA 510(k) eSTAR Mock Review provides an additional means of examining submission readiness and identifying potential deficiencies before FDA review.

The goal is not simply to prepare a submission. It is to establish the right regulatory strategy and identify the evidence needed to support it.

---

Primary regulatory sources

1. FDA, Medical Devices; Exemptions From Premarket Notification: Class II Devices; Certain Clinical Toxicology Test Systems, 91 FR 63478, October 6, 2026. Federal Register final order.
2. FDA, Medical Devices; Exemption From Premarket Notification: Radiology Computer-Aided Detection and/or Diagnosis Devices and Computer-Aided Triage and Notification Devices, 91 FR 58817, September 17, 2026. Federal Register final order.
3. FDA, Class I and Class II Device Exemptions. FDA overview.
4. FDA, Procedures for Class II Device Exemptions from Premarket Notification. FDA guidance.

This article provides general regulatory information and does not constitute an FDA classification or exemption determination for a specific device.